Raising expectations for subunit vaccine

Journal of Infectious Diseases

Volumn 211, Issue 9, 2015, Pages 1373-1375

  Schiller, John T ^a   Lowy, Douglas R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antibody; HBV; HPV; Memory B cell; Plasma cell; Prophylactic vaccine; Virus like particle

Indexed keywords

ALUMINUM SALT; HEPATITIS B VACCINE; INACTIVATED VIRUS VACCINE; LIVE VACCINE; MALARIA VACCINE; MEMBRANE ANTIGEN; NEUTRALIZING ANTIBODY; PHOSPHORYL LIPID A; TOLL LIKE RECEPTOR AGONIST; WART VIRUS VACCINE; SUBUNIT VACCINE; VIRUS ANTIBODY; VIRUS LIKE PARTICLE VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY RESPONSE; ANTIBODY TITER; B LYMPHOCYTE; DRUG EFFICACY; HEPATITIS; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; MEMORY CELL; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; UTERINE CERVIX DYSPLASIA; VIRION; VIRUS LIKE AGENT; ANIMAL; BLOOD; IMMUNIZATION; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS;

ANIMALS; ANTIBODIES, VIRAL; HUMANS; IMMUNIZATION SCHEDULE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; VACCINES, SUBUNIT; VACCINES, VIRUS-LIKE PARTICLE;

EID: 84928905846     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu648     Document Type: Review

References (21)

1. Plotkin SA. Vaccines: past, present and future. Nat Med 2005; 11(4 suppl):S5-11.
2. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papilloma-virus prophylactic vaccines. Vaccine 2012; 30(suppl 5):F123-38.
3. Roteli-Martins C, Naud P, De Borba P, et al. Sustained immunogenicity and efficacy of the HPV-16/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up. Hum Vaccin Immun-other 2012; 8:390-7.
4. Amanna IJ, Slifka MK. Contributions of humoral and cellular immunity to vaccine-induced protection in humans. Virology 2011; 411:206-15.
5. Amanna IJ, Carlson NE, Slifka MK. Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 2007; 357: 1903-15.
6. Safaeian M, Porras C, Pan Y, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) 2013; 6:1242-50.
7. Amanna IJ, Slifka MK. Mechanisms that determine plasma cell lifespan and the duration of humoral immunity. Immunol Rev 2010; 236:125-38.
8. Kreimer AR, Rodriguez AC, Hildesheim A, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011; 103:1444-51.
9. Longet S, Schiller JT, Bobst M, Jichlinski P, Nardelli-Haefliger D. A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. J Virol 2011; 85: 13253-9.
10. Bachmann MF, Rohrer UH, Kundig TM, Burki K, Hengartner H, Zinkernagel RM. The influence of antigen organization on B cell responsiveness. Science 1993; 262: 1448-51.
11. Bachmann MF, Whitehead P. Active immu-notherapy for chronic diseases. Vaccine 2013; 31:1777-84.
12. Chackerian B, Lowy DR, Schiller JT. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest 2001; 108:415-23.
13. Amanna IJ, Raue HP, Slifka MK. Development of a new hydrogen peroxide-based vaccine platform. Nat Med 2012; 18:974-9.
14. Garcon N, Wettendorff M, Van Mechelen M. Role of AS04 in human papillomavirus vaccine: mode of action and clinical profile. Expert Opin Biol Ther 2011; 11:667-77.
15. DeFranco AL, Rookhuizen DC, Hou B. Contribution of Toll-like receptor signaling to germinal center antibody responses. Immunol Rev 2012; 247:64-72.
16. Mulder AM, Carragher B, Towne V, et al. Toolbox for non-intrusive structural and functional analysis of recombinant VLP based vaccines: a case study with hepatitis B vaccine. PLoS One 2012; 7:e33235.
17. Mendy M, Peterson I, Hossin S, et al. Observational study of vaccine efficacy 24 years after the start of hepatitis B vaccination in two Gambian villages: no need for a booster dose. PLoS One 2013; 8:e58029.
18. Wistrom J, Ahlm C, Lundberg S, Settergren B, Tarnvik A. Booster vaccination with re-combinant hepatitis B vaccine four years after priming with one single dose. Vaccine 1999; 17:2162-5.
19. Schiller JT, Lowy DR. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nature Rev Microbiol 2012; 10:681-92.
20. Vaughan AM, Kappe SH. Malaria vaccine development: persistent challenges. Curr Opin Immunol 2012; 24:324-31.
21. Banatvala JE, Van Damme P. Hepatitis B vaccine-do we need boosters? J Viral Hepat 2003; 10:1-6.